<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1229">
  <stage>Registered</stage>
  <submitdate>11/07/2006</submitdate>
  <approvaldate>11/07/2006</approvaldate>
  <nctid>NCT00351598</nctid>
  <trial_identification>
    <studytitle>Lung Tumour Volume Database</studytitle>
    <scientifictitle>Tumour Volume as an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer - A Protocol for a Prospective Database.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TROG 99.05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - Definitive Radiotherapy

1 - Patients with loco-regional, NSCLC treated by definitive radiotherapy.


Treatment: other: Definitive Radiotherapy
60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival - Survival duration defined as the time from date of registration until death from any cause</outcome>
      <timepoint>End of Study</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Must satisfy ALL of the following

          -  NSCLC - histological or cytological diagnosis of non-small cell lung cancer

          -  Intra-thoracic disease - disease is confined to the primary site, with or without
             intrathoracic lymph nodes

          -  CT planning - CT imaging of the thorax has been performed as part of the planning
             procedure

          -  Definitive radiotherapy - it is planned to give definitive radiotherapy with or
             without chemotherapy (prior to, during or after radiotherapy). Definitive radiotherapy
             is defined as 60 Gy in 6 weeks, 50 Gy in 4 weeks or at least the equivalent of either
             of these. The size of each individual; fraction should not exceed 2.5 Gy.

          -  Measurable disease - the primary tumour and nodes with maximum diameter greater than
             1cm represent measurable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>A patient satisfying ANY of the following is ineligible

          -  Symptomatic or radiological evidence of metastatic disease

          -  Prior treatment for non-small cell lung cancer

          -  Surgical resection is part of initial treatment

          -  Palliative radiotherapy planned</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>531</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Newcastle Mater Misericordiae Hospital - Newcastle</hospital>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Mater QRI - South Brisbane</hospital>
    <hospital>East Coast Cancer Centre - Tugun</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Alfred Hospital - Prahran</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>1871 - Liverpool</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3081 - Heidelberg</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Peter MacCallum Cancer Centre, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main aim is to determine, in patients with locoregional, non-small cell lung cancer
      (NSCLC) treated by definitive radiotherapy, the influence on survival of the volume of
      primary tumour, as measured from CT imaging, after adjusting for the effect of the current
      TNM staging system and other known prognostic factors (especially ECOG performance and weight
      loss).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00351598</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Ball</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>